Replies to post #105363 on Biotech Values

[jq1234]

From here out, I'm valuing Momenta as if they are in the normal "Exclusivity" period just like any normal generic. Of course the longer it lasts the better.

Hey, you finally got it. That's how the market is valuing MNTA right now.

[pollyvonwog]

Obtaining Generic Lovenox has more to do with Teva's pride rather than its profits

That's my point I guess. TEVA has made it a mission of sorts to talk about their m-enox application whenever they can. It seems like they have a bit of a vendetta against MNTA, so I wonder why they wouldn't take the 10 seconds to mention the inspection since they found time to issue a press release the day of MNTA's approval. They certainly found time to mention that they submitted immunological data 30 days after MNTA, which I find less material than the inspections.

[biomaven0]

Obtaining Generic Lovenox has more to do with Teva's pride rather than its profits.

I don't agree. In the case where both get approved, we've been estimating that MNTA still clears $40m/yr based on a 10% profit share. Teva of course gets 100% of its profits, so we are talking potential profits to them of $350m/yr for a long time (not just the normal 6 months of exclusivity). That's about a 15% bump in their EPS.

Peter